GlassScriptPhysician profile
Anyeli Burdier
NPI 1053848945
$3,319.98
in general payments reported to CMS, 2019-2025
24 companies · $923 in 2025
The $923 reported for 2025 was more than what 83% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.28 · 2022: $280 · 2023: $1,023 · 2024: $1,047 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,992.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $892.08 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $465.68 | 2022-2025 | |
| Lilly USA, LLC | $380.74 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $348.21 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Exact Sciences Corporation | $236.43 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $173.75 | 2023-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $147.00 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.34 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $89.89 | 2022-2025 | Shingrix, Trelegy Ellipta |
| Dynavax Technologies Corporation | $61.31 | 2023-2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $52.46 | 2024-2025 | Voquezna |
| Pfizer INC. | $43.47 | 2023-2024 | |
| Axonics, INC. | $40.21 | 2022-2023 | Axonics |
| Merck Sharp & Dohme LLC | $38.44 | 2024-2025 | Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.38 | 2024-2025 | Xifaxan |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $33.16 | 2021-2025 | |
| Daiichi Sankyo INC. | $28.06 | 2024 | Injectafer |
| Astellas Pharma US INC | $27.23 | 2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $27.11 | 2022-2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $21.23 | 2021 | |
| Averitas Pharma INC. | $19.99 | 2024 | Qutenza |
| Sanofi Pasteur INC. | $16.27 | 2023 | |
| Abbvie INC. | $15.41 | 2025 | |
| Amarin Pharma, INC. | $15.13 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anyeli Burdier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.